EP3213748B1 - Cannabinoids (thc:cbd ratio) in combination with an alkylating agent for use in treating brain tumour - Google Patents
Cannabinoids (thc:cbd ratio) in combination with an alkylating agent for use in treating brain tumour Download PDFInfo
- Publication number
- EP3213748B1 EP3213748B1 EP16201983.0A EP16201983A EP3213748B1 EP 3213748 B1 EP3213748 B1 EP 3213748B1 EP 16201983 A EP16201983 A EP 16201983A EP 3213748 B1 EP3213748 B1 EP 3213748B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- thc
- cbd
- combination
- cannabidiol
- cannabinoids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930003827 cannabinoid Natural products 0.000 title claims description 63
- 239000003557 cannabinoid Substances 0.000 title claims description 63
- 229940065144 cannabinoids Drugs 0.000 title claims description 35
- 208000003174 Brain Neoplasms Diseases 0.000 title claims description 20
- 229940100198 alkylating agent Drugs 0.000 title claims description 13
- 239000002168 alkylating agent Substances 0.000 title claims description 13
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 90
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 90
- 229960004242 dronabinol Drugs 0.000 claims description 90
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 82
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 82
- 229950011318 cannabidiol Drugs 0.000 claims description 82
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 82
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 82
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 238000011282 treatment Methods 0.000 claims description 20
- 206010018338 Glioma Diseases 0.000 claims description 17
- 230000003833 cell viability Effects 0.000 claims description 16
- 230000000259 anti-tumor effect Effects 0.000 claims description 15
- 208000032612 Glial tumor Diseases 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 239000000419 plant extract Substances 0.000 claims description 9
- 230000010261 cell growth Effects 0.000 claims description 8
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 229940088679 drug related substance Drugs 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 4
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 4
- 229960005243 carmustine Drugs 0.000 claims description 4
- 229960004961 mechlorethamine Drugs 0.000 claims description 4
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 4
- 229960004964 temozolomide Drugs 0.000 claims description 4
- 229960001055 uracil mustard Drugs 0.000 claims description 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 claims description 2
- LYHRBIAPWZFXBG-UHFFFAOYSA-N 7h-imidazo[4,5-e]tetrazine Chemical class N1=NNC2=NC=NC2=N1 LYHRBIAPWZFXBG-UHFFFAOYSA-N 0.000 claims description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 2
- 229960000473 altretamine Drugs 0.000 claims description 2
- 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229960001052 streptozocin Drugs 0.000 claims description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 2
- 229960001196 thiotepa Drugs 0.000 claims description 2
- 150000004654 triazenes Chemical class 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 47
- 201000011510 cancer Diseases 0.000 description 26
- 239000000284 extract Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 206010003571 Astrocytoma Diseases 0.000 description 9
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 241000218236 Cannabis Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 3
- 101000607335 Homo sapiens Serine/threonine-protein kinase ULK1 Proteins 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102200082402 rs751610198 Human genes 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010035104 Pituitary tumour Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100039988 Serine/threonine-protein kinase ULK1 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- -1 ethanol) Chemical class 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 201000004058 mixed glioma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 229960000665 norflurane Drugs 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) in a ratio of from 5:1 to 1:5 together with an alkylating agent for use in the treatment of a brain tumour, wherein the THC and / or CBD is present in an amount which would be considered sub-optimal if it were used alone.
- THC cannabinoids tetrahydrocannabinol
- CBD cannabidiol
- Cancer a disease in which a group of cells display the traits of uncontrolled growth. This means that the cells grow and divide beyond the levels of normal limits. The cells are also able to invade and destroy surrounding tissues. In addition cancer cells sometimes also metastasize, meaning that they spread to other locations in the body via the blood or lymph.
- cancers are caused by abnormalities in the genetic material of the cells. These abnormalities may be due to the effects of carcinogens. Other cancer-promoting genetic abnormalities may be randomly acquired through errors in DNA replication, or are inherited, and thus present in all cells from birth.
- Cancer-promoting oncogenes are often activated in cancer cells, giving those cells new properties, such as hyperactive growth and division, protection against programmed cell death, loss of respect for normal tissue boundaries, and the ability to become established in diverse tissue environments.
- Tumour suppressor genes are often inactivated in cancer cells, resulting in the loss of normal functions in those cells, such as accurate DNA replication, control over the cell cycle, orientation and adhesion within tissues, and interaction with protective cells of the immune system.
- cancer There are many different types of cancer and the cancer is usually classified according to the type of tissue from which it originated.
- Cancer is usually treated by one or more of the following: surgery, chemotherapy, radiation therapy, immunotherapy and monoclonal antibody therapy.
- the type of therapy depends upon the location and grade of the tumour and the stage of the disease.
- Cancers are known to affect many areas of the body with the most common types of cancers including: cancer of the bile duct, cancer of the bladder, cancer of the bone, cancer of the bowel (including cancer of the colon and cancer of the rectum), cancer of the brain, cancer of the breast, cancer of the neuroendocrine system (commonly known as a carcinoid), cancer of the cervix, cancer of the eye, cancer of the oesophagus, cancer of the head and neck (this group includes carcinomas that start in the cells that form the lining of the mouth, nose, throat, ear or the surface layer covering the tongue), Kaposi's sarcoma, cancer of the kidney, cancer of the larynx, leukaemia, cancer of the liver, cancer of the lung, cancer of the lymph nodes, Hodgkin's lymphoma, non-Hodgkin's lymphoma, melanoma, mesothelioma, myeloma, cancer of the ovary, cancer of
- a tumour that develops in the brain can destroy or damage brain cells by producing inflammation, compressing other parts of the brain, inducing cerebral oedema (brain swelling) and can cause increases in intracranial pressure (pressure within the skull).
- a primary brain tumour is a mass created by the growth or uncontrolled proliferation of cells in the brain. Malignant primary brain tumours are most likely to cause problems by spreading into the normal brain tissue which surrounds them and causing pressure and damage to the surrounding areas of the brain. These tumours rarely spread outside the brain to other parts of the body. However, secondary brain tumours occur when cancer cells from other parts of the body, such as the lung or breast spread to the brain.
- Surgery is the treatment option of choice for many brain tumours. Some may be completely excised, but those that are deep or that infiltrate brain tissue may be debulked rather than removed.
- Radiotherapy and chemotherapy may be recommended depending on the type of tumour involved.
- Glioma cell tumours can often be lethal.
- the characteristic diffuse infiltrative tumour growth of gliomas often makes the surgical removal of them impossible and this profoundly complicates the clinical management of these patients.
- Glioblastoma multiforme is the most common and most aggressive type of primary brain tumour and accounts for 52% of all primary brain tumour cases and 20% of all intracranial tumours.
- Cannabinoids are the active constituents of cannabis plants and they have been found to demonstrate numerous pharmacological properties.
- EP1177790 (Guzman et al. ) describes the treatment of cerebral tumours by the administration of a natural or synthetic cannabinoid, specifically THC. It is claimed that activation of specific receptors leads to selective death of the transformed cells.
- Biochemical Pharmacology 2000, vol 6, p1807-1813 compared the effects of cannabinoids including THC and CBD with the estrogen receptor modulator Tamoxifen and concluded that the effects of the cannabinoids were modest and that there was no significant interaction between them and Tamoxifen.
- gliomas are highly infiltrative and proliferative tumours, which follow a characteristic pattern of growth. Glioma cells invade the adjacent normal brain structures and surrounding large blood vessels.
- the present invention there is provided a combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) in a ratio of from 5:1 to 1:5 together with an alkylating agent for use in the treatment of a brain tumour wherein the THC and/ or CBD is present in an amount which would be considered sub-optimal if it were used alone.
- THC cannabinoids tetrahydrocannabinol
- CBD cannabidiol
- the THC is present in an amount which would be considered sub-optimal if it were used alone
- the CBD is present in an amount which would be considered sub-optimal if it were used alone.
- the THC and CBD are present in an amount which would be considered sub-optimal if they were used alone.
- the treatment of the brain tumour is to reduce cell viability, inhibit cell growth or reduce tumour volume.
- the THC and CBD are in the ratio of from between 2:1 to 1:2, more approximately 1:1.
- Each cannabinoid is provided in a therapeutically effect amount.
- Dose ranges for the THC and CBD may be determined by reference to the cannabinoid content which is preferably in the range of between 5 and 100mg of the total cannabinoids.
- alkylating agent is a type of anti-neoplastic agent that works by interfering with DNA in a number of ways.
- alkyl groups Extra molecules, called alkyl groups, are added to DNA, which causes it to break apart as the cell tries to replace them. Alkylating agents also interfere with the bonds between DNA strands, stopping them from separating, which is a step required in DNA replication. By replacing bases (important components of DNA) alkylating agents also create mismatching, another way to stop DNA being reproduced properly.
- the alkylating agent is selected from the group consisting of: alkyl sulfonates; busulfan; ethyleneimines and methylmelamines; hexamethymelamine; altretamine; thiotepa; nitrogen mustards; cyclophosphamide; mechlorethamine; mustine; uramustine; uracil mustard; melphalan; chlorambucil; ifosfamide; nitrosureas; carmustine; cisplatin; streptozocin; triazenes; decarbazine; imidazotetrazines; and temozolomide.
- Alkylating agents used as anti-tumoural agents include: cisplatin, temozolamide and carmustine and these are preferred in the practice of the present invention.
- Brain tumours are usually classified according to the location of the tumour and the type of cell that the cancer has developed from.
- brain tumour examples include: acoustic neuroma, astrocytoma, CNS lymphoma, ependymoma, haemangioblastoma, medulloblastoma, meningioma, glioma, mixed glioma, oligodendroglioma, pineal region tumours and pituitary tumours.
- Gliomas are tumours of the glial cells; these cells support and protect nerve cells in the brain. Gliomas comprise nearly half of all primary brain tumours and a fifth of all primary spinal cord tumours.
- the combined therapy of the invention is particularly useful where the brain tumour is a glioma tumour, more particularly glioblastoma multiforme (GBM).
- GBM glioblastoma multiforme
- the one or more cannabinoids may be present as plant extracts, as pure compounds, or a combination of the two.
- a plant extract is defined as an extract from a plant material as described by the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research .
- Plant material is defined as a plant or plant part (e.g. bark, wood, leaves, stems, roots, flowers, fruits, seeds, berries or parts thereof) as well as exudates.
- the plant extract is in the form of a botanical drug substance.
- a botanical drug substance is defined as follows.
- Botanical drug substances which are derived from cannabis plants include primary extracts prepared by such processes as for example, maceration, percolation, extraction with solvents such as C1 to C5 alcohols (e.g. ethanol), Norflurane (HFA134a), HFA227, liquid carbon dioxide under pressure and extraction using a hot gas.
- the primary extract may be further purified by supercritical or subcritical extraction, vaporisation and chromatography. When solvents such as those listed above are used the resultant extract may contain non-specific lipid-soluble material. This can be removed by a variety of processes including winterisation, which involves chilling to -20°C followed by filtration to remove waxy ballast, extraction with liquid carbon dioxide and by distillation.
- Botanical drug substances are formulated into Botanical Drug Products which are defined in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research as: "A botanical product that is intended for use as a drug; a drug product that is prepared from a botanical drug substance .”
- the one or more cannabinoids may be administered separately, sequentially or simultaneously to the non-cannabinoid anti-tumoural agent.
- the one or more cannabinoids may be presented together with the non-cannabinoid chemotherapeutic agent in the form of a kit together with or without instructions to their use.
- a medicine comprising the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) in a ratio of from 5:1 to 1:5 together with an alkylating agent.
- THC cannabinoids tetrahydrocannabinol
- CBD cannabidiol
- Example 6 goes on to demonstrate, using a single cannabinoid for illustrative purposes, how the combination of one or more cannabinoids with a non-cannabinoid anti-tumoural agent may be better than the use of the non-cannabinoid anti-tumoural agent alone.
- Tetrahydrocannabinol (THC) and cannabidiol (CBD) in the form of cannabis plant extracts were dissolved in ethanol to a concentration of 100mM this was stored at -20°C until required.
- the cannabis plant extracts were further diluted to the desired concentration, ensuring that the concentration of ethanol was below 0.001%.
- U87 human glioma cells were used throughout this experiment. The cells were maintained at 37°C in a humidified atmosphere with 5% CO 2 and 95% air.
- DMEM Dulbecco's Modified Eagle Medium
- the viability of the human U87 MG astrocytoma cells were examined at various cannabinoid concentrations.
- the THC and CBD extracts were compared against pure THC and CBD.
- Table 1 Cell viability of human U87 MG astrocytoma cells in culture IC50 ⁇ M (pure cannabinoids) IC50 ⁇ M (cannabis plant extract) IC50 ⁇ M (equivalent of pure in cannabis plant extract) THC 0.37 0.64 0.43 CBD 0.47 0.72 0.47
- THC and CBD extracts compare very favourably in activity to their corresponding pure compounds, when the amount of cannabinoid in the extract is adjusted to an equivalent amount of pure compound.
- THC and CBD and their extracts are effective in inhibiting glioma cell growth.
- This experiment tested whether a combination of THC and CBD extracts were as effective at inhibiting cell growth as the extracts alone.
- Figure 1 details a bar chart describing the cell viability of human U87 MG astrocytoma cells versus the THC and CBD extracts alone and in combination with one another.
- the cell viability is significantly reduced in comparison to the cell viability after treatment with either THC or CBD alone.
- Tumour volume relative to zero time following 15 days of treatment
- Tumour volume Vehicle 9.2 ⁇ 0.6 Pure THC 5.1 ⁇ 0.4 THC extract 6.6 ⁇ 0.3 THC:CBD (1:1) extract 4.8 ⁇ 0.3
- tumour volume after treatment with the 1:1 combination of THC and CBD extracts is significantly superior to the treatment with either the pure THC or the THC extract alone.
- THC THC
- CBD THC
- T98G THC
- Figs 2a and 2b The cell viability data is illustrated in Figs 2a and 2b .
- Fig 2a it will be seen that ineffective / sub-optimal doses of THC and CBD at 0.1ug/ml and 0.25ug/ml (greater than 90% cell viability)gave way to a statistically significant decrease in cell viability in combination (SAT), which data showed a dose dependant relationship with increased concentration (greater cytotoxicity at 0.25ug/ml).
- SAT cell viability in combination
- cell line T98G (an alternative human glioma cell line) as is shown in Fig 2b .
- THC is known to induce cell death using a signalling route involving the gene ATG1 and pan-caspase.
- the results of an investigation looking at S6 phosphorylation, LC3 lipidation and the effect of an ATG1 and a pan-caspase inhibitor are shown in Figs 3a, 3b and 3c respectively.
- Fig 3b shows that silencing the essential autophagy gene ATG1, with a selective (siATG10) siRNA inhibitor reduces induced cell death compared to cells transfected with a control siC.
- Fig 3c shows that cells treated with the pancapase inhibitor Z-VAD also prevent induced cell death.
- Figures 4 and 5 detail bar charts which illustrate the cell viability of human U87 MG astrocytoma cells when treated with either THC, an anti-tumoural agent or a combination of the two versus a control.
- Examples 1 to 6 demonstrate that the combination of one or more cannabinoids with a non-cannabinoid anti-tumoural drug produces a more beneficial effect than the use of the non-cannabinoid anti-tumoural drug alone.
Description
- The present invention relates to a combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) in a ratio of from 5:1 to 1:5 together with an alkylating agent for use in the treatment of a brain tumour, wherein the THC and / or CBD is present in an amount which would be considered sub-optimal if it were used alone.
- Cancer a disease in which a group of cells display the traits of uncontrolled growth. This means that the cells grow and divide beyond the levels of normal limits. The cells are also able to invade and destroy surrounding tissues. In addition cancer cells sometimes also metastasize, meaning that they spread to other locations in the body via the blood or lymph.
- Most cancers are caused by abnormalities in the genetic material of the cells. These abnormalities may be due to the effects of carcinogens. Other cancer-promoting genetic abnormalities may be randomly acquired through errors in DNA replication, or are inherited, and thus present in all cells from birth.
- Genetic abnormalities found in cancer typically affect two general classes of genes. Cancer-promoting oncogenes are often activated in cancer cells, giving those cells new properties, such as hyperactive growth and division, protection against programmed cell death, loss of respect for normal tissue boundaries, and the ability to become established in diverse tissue environments.
- Tumour suppressor genes are often inactivated in cancer cells, resulting in the loss of normal functions in those cells, such as accurate DNA replication, control over the cell cycle, orientation and adhesion within tissues, and interaction with protective cells of the immune system.
- There are many different types of cancer and the cancer is usually classified according to the type of tissue from which it originated.
- Cancer is usually treated by one or more of the following: surgery, chemotherapy, radiation therapy, immunotherapy and monoclonal antibody therapy. The type of therapy depends upon the location and grade of the tumour and the stage of the disease.
- Complete removal of the cancer without damage to the rest of the body is the goal of treatment. Sometimes this can be accomplished by surgery, but the propensity of cancers to invade adjacent tissue or to spread to distant sites by microscopic metastasis often limits its effectiveness. The effectiveness of chemotherapy is often limited by toxicity to other tissues in the body. Radiation can also cause damage to normal tissue.
- Cancers are known to affect many areas of the body with the most common types of cancers including: cancer of the bile duct, cancer of the bladder, cancer of the bone, cancer of the bowel (including cancer of the colon and cancer of the rectum), cancer of the brain, cancer of the breast, cancer of the neuroendocrine system (commonly known as a carcinoid), cancer of the cervix, cancer of the eye, cancer of the oesophagus, cancer of the head and neck (this group includes carcinomas that start in the cells that form the lining of the mouth, nose, throat, ear or the surface layer covering the tongue), Kaposi's sarcoma, cancer of the kidney, cancer of the larynx, leukaemia, cancer of the liver, cancer of the lung, cancer of the lymph nodes, Hodgkin's lymphoma, non-Hodgkin's lymphoma, melanoma, mesothelioma, myeloma, cancer of the ovary, cancer of the pancreas, cancer of the penis, cancer of the prostate, skin cancer, soft tissue sarcomas, cancer of the spinal cord, cancer of the stomach, testicular cancer, cancer of the thyroid, cancer of the vagina, cancer of the vulva and cancer of the uterus.
- A tumour that develops in the brain can destroy or damage brain cells by producing inflammation, compressing other parts of the brain, inducing cerebral oedema (brain swelling) and can cause increases in intracranial pressure (pressure within the skull).
- Each year, approximately 4300 people in the UK are diagnosed with a brain tumour. A primary brain tumour is a mass created by the growth or uncontrolled proliferation of cells in the brain. Malignant primary brain tumours are most likely to cause problems by spreading into the normal brain tissue which surrounds them and causing pressure and damage to the surrounding areas of the brain. These tumours rarely spread outside the brain to other parts of the body. However, secondary brain tumours occur when cancer cells from other parts of the body, such as the lung or breast spread to the brain.
- Surgery is the treatment option of choice for many brain tumours. Some may be completely excised, but those that are deep or that infiltrate brain tissue may be debulked rather than removed.
- Radiation therapy and chemotherapy may be recommended depending on the type of tumour involved.
- Glioma cell tumours can often be lethal. The characteristic diffuse infiltrative tumour growth of gliomas often makes the surgical removal of them impossible and this profoundly complicates the clinical management of these patients.
- Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain tumour and accounts for 52% of all primary brain tumour cases and 20% of all intracranial tumours.
- Different approaches are being researched in order to improve the mortality rate of patients diagnosed with a glioma. These include therapies that target the glioma cells but leave normal cells unharmed, methods that limit the spread of the cancer cells and treatments that block the tumours life-sustaining molecules.
- One such area of research involves the use of cannabinoids as anti-tumoural agents.
- Cannabinoids are the active constituents of cannabis plants and they have been found to demonstrate numerous pharmacological properties.
- For example
EP1177790 (Guzman et al. ) describes the treatment of cerebral tumours by the administration of a natural or synthetic cannabinoid, specifically THC. It is claimed that activation of specific receptors leads to selective death of the transformed cells. - Recently the cannabinoid CBD has been shown to possess anti-tumoural properties (Massi et al. 2004). The work described by this paper describes anti-proliferative effects both in-vitro using U87 and U373 human glioma cell lines and in-vivo using U87 human glioma cells subcutaneously implanted to nude mice.
- Biochemical Pharmacology 2000, vol 6, p1807-1813 compared the effects of cannabinoids including THC and CBD with the estrogen receptor modulator Tamoxifen and concluded that the effects of the cannabinoids were modest and that there was no significant interaction between them and Tamoxifen.
- Malignant gliomas are highly infiltrative and proliferative tumours, which follow a characteristic pattern of growth. Glioma cells invade the adjacent normal brain structures and surrounding large blood vessels.
- In addition the applicant's earlier patent
EP1802274 describes the use of the cannabinoid CBD to impede the progress of cancer cells migrating from their primary tumour location to a secondary site. - The applicant's co-pending application
GB0810195.8, filed on 4 June 2008 - According to the present invention there is provided a combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) in a ratio of from 5:1 to 1:5 together with an alkylating agent for use in the treatment of a brain tumour wherein the THC and/ or CBD is present in an amount which would be considered sub-optimal if it were used alone.
- Preferably the THC is present in an amount which would be considered sub-optimal if it were used alone Alternatively the CBD is present in an amount which would be considered sub-optimal if it were used alone. In a further embodiment the THC and CBD are present in an amount which would be considered sub-optimal if they were used alone.
- Preferably the treatment of the brain tumour is to reduce cell viability, inhibit cell growth or reduce tumour volume.
- More preferably still, the THC and CBD are in the ratio of from between 2:1 to 1:2, more approximately 1:1.
- Each cannabinoid is provided in a therapeutically effect amount. Dose ranges for the THC and CBD may be determined by reference to the cannabinoid content which is preferably in the range of between 5 and 100mg of the total cannabinoids.
- An alkylating agent is a type of anti-neoplastic agent that works by interfering with DNA in a number of ways.
- Extra molecules, called alkyl groups, are added to DNA, which causes it to break apart as the cell tries to replace them. Alkylating agents also interfere with the bonds between DNA strands, stopping them from separating, which is a step required in DNA replication. By replacing bases (important components of DNA) alkylating agents also create mismatching, another way to stop DNA being reproduced properly.
- All these changes occur when a cell is preparing to divide, and the permanent damage they cause results in cessation of division and cell death.
- Preferably the alkylating agent is selected from the group consisting of: alkyl sulfonates; busulfan; ethyleneimines and methylmelamines; hexamethymelamine; altretamine; thiotepa; nitrogen mustards; cyclophosphamide; mechlorethamine; mustine; uramustine; uracil mustard; melphalan; chlorambucil; ifosfamide; nitrosureas; carmustine; cisplatin; streptozocin; triazenes; decarbazine; imidazotetrazines; and temozolomide.
- Alkylating agents used as anti-tumoural agents include: cisplatin, temozolamide and carmustine and these are preferred in the practice of the present invention.
- Brain tumours are usually classified according to the location of the tumour and the type of cell that the cancer has developed from.
- For example different types of brain tumour include: acoustic neuroma, astrocytoma, CNS lymphoma, ependymoma, haemangioblastoma, medulloblastoma, meningioma, glioma, mixed glioma, oligodendroglioma, pineal region tumours and pituitary tumours.
- Gliomas are tumours of the glial cells; these cells support and protect nerve cells in the brain. Gliomas comprise nearly half of all primary brain tumours and a fifth of all primary spinal cord tumours.
- The combined therapy of the invention is particularly useful where the brain tumour is a glioma tumour, more particularly glioblastoma multiforme (GBM).
- The one or more cannabinoids may be present as plant extracts, as pure compounds, or a combination of the two.
- A plant extract is defined as an extract from a plant material as described by the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research.
- Plant material is defined as a plant or plant part (e.g. bark, wood, leaves, stems, roots, flowers, fruits, seeds, berries or parts thereof) as well as exudates.
- More preferably the plant extract is in the form of a botanical drug substance.
- A botanical drug substance is defined as follows. Botanical drug substances which are derived from cannabis plants include primary extracts prepared by such processes as for example, maceration, percolation, extraction with solvents such as C1 to C5 alcohols (e.g. ethanol), Norflurane (HFA134a), HFA227, liquid carbon dioxide under pressure and extraction using a hot gas. The primary extract may be further purified by supercritical or subcritical extraction, vaporisation and chromatography. When solvents such as those listed above are used the resultant extract may contain non-specific lipid-soluble material. This can be removed by a variety of processes including winterisation, which involves chilling to -20°C followed by filtration to remove waxy ballast, extraction with liquid carbon dioxide and by distillation.
- Botanical drug substances are formulated into Botanical Drug Products which are defined in the Guidance for Industry Botanical Drug Products Draft Guidance, August 2000, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research as: "A botanical product that is intended for use as a drug; a drug product that is prepared from a botanical drug substance."
- The one or more cannabinoids may be administered separately, sequentially or simultaneously to the non-cannabinoid anti-tumoural agent.
- The one or more cannabinoids may be presented together with the non-cannabinoid chemotherapeutic agent in the form of a kit together with or without instructions to their use.
- In accordance with a second aspect of the present invention there is provided a medicine comprising the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) in a ratio of from 5:1 to 1:5 together with an alkylating agent.
- Certain aspects of this invention are further described, by way of example only, with reference to the accompanying drawings in which:
-
Figure 1 is a bar chart showing the cell viability of human U87 MG astrocytoma cells after treatment with THC, CBD or a combination of THC and CBD in comparison to a control; -
Figures 2a and 2b are bar charts showing in vivo cell viability data at different concentrations on two cell lines, U87MG (Fig 2a ) and T98G (Fig 2b ); -
Figures 3a, 3b and3c provide data suggestive of the mechanism of action of the combination for U87MG cells. -
Figure 4 is a bar chart showing the cell viability of human U87 MG astrocytoma cells after treatment with an exemplary cannabinoid, THC, or a combination of an exemplary cannabinoid THC and an exemplary non-cannabinoid anti-tumour agent, tamoxifen in comparison to a control; and -
Figure 5 is a bar chart showing the cell viability of human U87 MG astrocytoma cells after treatment with an exemplary cannabinoid THC, or a combination of an exemplary cannabinoid THC and an exemplary non-cannabinoid anti-tumour agent, cisplatin in comparison to a control. - The following examples 1 to 5 illustrate how one or more cannabinoids are effective in the treatment of cancer cells both in vitro and in vivo.
- Example 6 goes on to demonstrate, using a single cannabinoid for illustrative purposes, how the combination of one or more cannabinoids with a non-cannabinoid anti-tumoural agent may be better than the use of the non-cannabinoid anti-tumoural agent alone.
- Tetrahydrocannabinol (THC) and cannabidiol (CBD) in the form of cannabis plant extracts were dissolved in ethanol to a concentration of 100mM this was stored at -20°C until required.
- Before use the cannabis plant extracts were further diluted to the desired concentration, ensuring that the concentration of ethanol was below 0.001%.
- U87 human glioma cells were used throughout this experiment. The cells were maintained at 37°C in a humidified atmosphere with 5% CO2 and 95% air.
- Cells were cultured in a 75cm2 culture flask in Dulbecco's Modified Eagle Medium (DMEM), which had been supplemented with 4mM L-glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin, 1% sodium pyruvate, 1% non-essential amino acids and 10% heat-inactivated fetal bovine serum.
- The viability of the human U87 MG astrocytoma cells were examined at various cannabinoid concentrations. The THC and CBD extracts were compared against pure THC and CBD.
-
Table 1: Cell viability of human U87 MG astrocytoma cells in culture IC50 µM (pure cannabinoids) IC50 µM (cannabis plant extract) IC50 µM (equivalent of pure in cannabis plant extract) THC 0.37 0.64 0.43 CBD 0.47 0.72 0.47 - As can be seen from Table 1 above the THC and CBD extracts compare very favourably in activity to their corresponding pure compounds, when the amount of cannabinoid in the extract is adjusted to an equivalent amount of pure compound.
- This shows that THC and CBD and their extracts are effective in inhibiting glioma cell growth.
- This experiment tested whether a combination of THC and CBD extracts were as effective at inhibiting cell growth as the extracts alone.
- The methods used were as described in Example 1 above.
-
Figure 1 details a bar chart describing the cell viability of human U87 MG astrocytoma cells versus the THC and CBD extracts alone and in combination with one another. - As can be seen when the THC and CBD are used in combination the cell viability is significantly reduced in comparison to the cell viability after treatment with either THC or CBD alone.
- This data suggests that the cannabinoids THC and CBD would be more effective in the treatment of tumours when used in combination.
- This experiment tested whether the combination of THC and CBD extracts were also effective in vivo.
- Human U87 MG astrocytoma cells were xenografted to nude mice and the test compounds were injected peritumourally at a concentration of 15 mg/kg per day.
-
Table 2: Tumour volume relative to zero time following 15 days of treatment Tumour volume Vehicle 9.2 ± 0.6 Pure THC 5.1 ± 0.4 THC extract 6.6 ± 0.3 THC:CBD (1:1) extract 4.8 ± 0.3 - As can be observed in Table 2 above the tumour volume after treatment with the 1:1 combination of THC and CBD extracts is significantly superior to the treatment with either the pure THC or the THC extract alone.
- This data suggests that the cannabinoids THC and CBD would be more effective in the treatment of tumours when used in combination.
- The action of THC, CBD, and a 1:1 ratio mix of THC and CBD were studied at different concentrations on two cell lines: U87MG and T98G. The cell viability data is illustrated in
Figs 2a and 2b . - Referring to
Fig 2a it will be seen that ineffective / sub-optimal doses of THC and CBD at 0.1ug/ml and 0.25ug/ml (greater than 90% cell viability)gave way to a statistically significant decrease in cell viability in combination (SAT), which data showed a dose dependant relationship with increased concentration (greater cytotoxicity at 0.25ug/ml). - Similar results were obtained with cell line T98G, (an alternative human glioma cell line) as is shown in
Fig 2b . - THC is known to induce cell death using a signalling route involving the gene ATG1 and pan-caspase. The results of an investigation looking at S6 phosphorylation, LC3 lipidation and the effect of an ATG1 and a pan-caspase inhibitor are shown in
Figs 3a, 3b and3c respectively. - It can be seen from
Fig 3a that the THC:CBD combination (compare to control C): - Inhibits mTORC1 activity (as determined by the levels of S6 phosphorylation);and
- Promotes accumulation of the lipidated form LC3 (a hall mark of autophagy).
-
Fig 3b shows that silencing the essential autophagy gene ATG1, with a selective (siATG10) siRNA inhibitor reduces induced cell death compared to cells transfected with a control siC. - Finally,
Fig 3c shows that cells treated with the pancapase inhibitor Z-VAD also prevent induced cell death. - This experiment tested whether a cannabinoid-containing medicine might be useful in combination with non-cannabinoid anti-tumoural agents.
- Cell viability assays were performed as described in Example 1 above.
-
Figures 4 and5 detail bar charts which illustrate the cell viability of human U87 MG astrocytoma cells when treated with either THC, an anti-tumoural agent or a combination of the two versus a control. - As can be seen from these figures both exemplary anti-tumoural agents that were tested; tamoxifen and cisplatin, were more efficient at reducing cell viability when used in combination with an exemplary cannabinoid, THC. It would be readily apparent from Examples 1 to 5 that similar benefits would be expected with CBD and a combination of THC and CBD.
- The combination of Examples 1 to 6 demonstrate that the combination of one or more cannabinoids with a non-cannabinoid anti-tumoural drug produces a more beneficial effect than the use of the non-cannabinoid anti-tumoural drug alone.
Claims (16)
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) in a ratio of from 5:1 to 1:5 together with an alkylating agent for use in the treatment of a brain tumour wherein the THC and/ or CBD is present in an amount which would be considered sub-optimal if it were used alone.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in claim 1 wherein the THC is present in an amount which would be considered sub-optimal if it were used alone.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in claim 1 wherein the CBD is present in an amount which would be considered sub-optimal if it were used alone.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in claim 1 wherein the THC and CBD are present in an amount which would be considered sub-optimal if they were used alone.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in any of the preceding claims, wherein the treatment of the brain tumour is to reduce cell viability, inhibit cell growth or reduce tumour volume.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in any of the preceding claims, wherein the THC and CBD are in the ratio of from between 2:1 to 1:2.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in any of the preceding claims, wherein the THC and CBD are in the ratio of approximately 1:1.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in any of the preceding claims, wherein the total cannabinoid content is in the range of between 5 and 100mg.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in claim 1, wherein the alkylating agent is selected from the group consisting of: alkyl sulfonates; busulfan; ethyleneimines and methylmelamines; hexamethymelamine; altretamine; thiotepa; nitrogen mustards; cyclophosphamide; mechlorethamine; mustine; uramustine; uracil mustard; melphalan; chlorambucil; ifosfamide; nitrosureas; carmustine; cisplatin; streptozocin; triazenes; decarbazine; imidazotetrazines; and temozolomide.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in claim 9, wherein the alkylating agent is one of: cisplatin; temozolomide; and carmustine.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in any of the preceding claims, wherein the brain tumour is a glioma tumour.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in claim 11, wherein the brain tumour is a glioblastoma multiforme (GBM).
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in any of the preceding claims, wherein the THC and CBD are present as plant extracts, as pure compounds, or a combination of the two.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in claim 13, wherein the plant extract is in the form of a botanical drug substance.
- A combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) for use as claimed in any of the preceding claims, wherein the THC and CBD are administered separately, sequentially or simultaneously to the non-cannabinoid anti-tumoural agent.
- A medicine comprising the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) in a ratio of from 5:1 to 1:5 together with an alkylating agent, wherein the THC and/or CBD is present in an amount which would be considered sub-optimal if it were used alone.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0810203.0A GB2460672B (en) | 2008-06-04 | 2008-06-04 | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents |
PCT/GB2009/050620 WO2009147438A1 (en) | 2008-06-04 | 2009-06-04 | Cannabinoids in combination with non -cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents) |
EP09757810.8A EP2320881B1 (en) | 2008-06-04 | 2009-06-04 | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents) |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09757810.8A Division EP2320881B1 (en) | 2008-06-04 | 2009-06-04 | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents) |
EP09757810.8A Division-Into EP2320881B1 (en) | 2008-06-04 | 2009-06-04 | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents) |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3213748A1 EP3213748A1 (en) | 2017-09-06 |
EP3213748B1 true EP3213748B1 (en) | 2021-08-18 |
Family
ID=39638156
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09757810.8A Active EP2320881B1 (en) | 2008-06-04 | 2009-06-04 | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents) |
EP16201983.0A Active EP3213748B1 (en) | 2008-06-04 | 2009-06-04 | Cannabinoids (thc:cbd ratio) in combination with an alkylating agent for use in treating brain tumour |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09757810.8A Active EP2320881B1 (en) | 2008-06-04 | 2009-06-04 | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents) |
Country Status (24)
Country | Link |
---|---|
US (3) | US20110086113A1 (en) |
EP (2) | EP2320881B1 (en) |
JP (2) | JP5674649B2 (en) |
KR (1) | KR20110053944A (en) |
CN (1) | CN102083426B (en) |
AR (1) | AR072002A1 (en) |
AU (1) | AU2009254935B2 (en) |
BR (1) | BRPI0911384A8 (en) |
CA (1) | CA2726257C (en) |
CO (1) | CO6341551A2 (en) |
DK (1) | DK2320881T3 (en) |
ES (2) | ES2887084T3 (en) |
GB (2) | GB2475183B (en) |
IL (1) | IL209739A0 (en) |
MX (1) | MX2010013036A (en) |
MY (1) | MY156264A (en) |
NZ (1) | NZ589373A (en) |
PT (1) | PT2320881T (en) |
RU (1) | RU2543034C2 (en) |
SG (1) | SG191643A1 (en) |
TW (1) | TWI469777B (en) |
UA (1) | UA104589C2 (en) |
WO (1) | WO2009147438A1 (en) |
ZA (1) | ZA201008558B (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008144475A1 (en) | 2007-05-17 | 2008-11-27 | California Pacific Medical Center | Methods and compositions for treating cancer |
GB2471987B (en) * | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
GB2554592B (en) * | 2010-03-12 | 2018-07-11 | Gw Pharma Ltd | A glioma treatment Comprising Temozolomide with a mixture of THA and CBD ar a ration of 1:1 |
GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
GB2494461A (en) | 2011-09-12 | 2013-03-13 | Gw Pharma Ltd | Phytocannabinoids for use in the treatment of invasive cancers or metastases |
GB201117956D0 (en) * | 2011-10-18 | 2011-11-30 | Otsuka Pharma Co Ltd | Phytocannabinoids for use in the treatment of breast cancer |
KR102427777B1 (en) | 2012-06-26 | 2022-08-01 | 델 마 파마슈티컬스 | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
GB201217285D0 (en) * | 2012-09-27 | 2012-11-14 | Univ Central Lancashire | Indole derivatives |
EP2719375A1 (en) * | 2012-10-10 | 2014-04-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms |
WO2014168986A1 (en) | 2013-04-08 | 2014-10-16 | Brown Dennis M | Therapeutic benefit of suboptimally administered chemical compounds |
GB2516814B (en) | 2013-06-19 | 2016-08-31 | Otsuka Pharma Co Ltd | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer |
DK3122426T3 (en) | 2014-03-28 | 2023-04-03 | Univ Duke | Treatment of breast cancer using selective estrogen receptor modulators |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
GB2527590A (en) | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
EP3250200A4 (en) | 2015-01-31 | 2018-09-19 | Constance Therapeutics, Inc. | Methods for preparation of cannabis oil extracts and compositions |
US10238745B2 (en) | 2015-01-31 | 2019-03-26 | Constance Therapeutics, Inc. | Cannabinoid composition and products including α-tocopherol |
US20170189373A1 (en) * | 2015-05-15 | 2017-07-06 | Andrew Hospodor | Terpene Control in Scaleable Cannabinoid Medicinal Formulations |
CA3187317A1 (en) * | 2015-10-27 | 2017-05-04 | Jay Pharma, Inc. | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
AU2016359160A1 (en) | 2015-11-24 | 2018-06-14 | Constance Therapeutics, Inc. | Cannabis oil compositions and methods for preparation thereof |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
CN111629724A (en) * | 2017-09-02 | 2020-09-04 | 科学控股公司 | Tetrahydrocannabinol modulators |
WO2020160452A1 (en) * | 2019-02-01 | 2020-08-06 | Tess Ventures, Inc. | Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies |
GB201903546D0 (en) * | 2019-03-15 | 2019-05-01 | Ldn Pharma Ltd | Cancer treatment |
US20220362168A1 (en) * | 2019-08-09 | 2022-11-17 | Jay Pharma Inc. | Administration regimes of cannabinoids in combination with chemotherapeutics against cancer |
WO2021034405A1 (en) * | 2019-08-19 | 2021-02-25 | Diverse Biotech, Inc. | Platinum complex anti-neoplastic agents comprising a cannabinoid ligand |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566560B2 (en) * | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
ES2164584A1 (en) * | 2000-02-11 | 2002-02-16 | Univ Madrid Complutense | Therapy with cannabinoids in the treatment of cerebral tumor |
US20040039048A1 (en) * | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
RU2166948C1 (en) * | 2000-05-29 | 2001-05-20 | Центральный научно-исследовательский рентгенорадиологический институт | Method for treating gliomae aggravated with epileptic syndrome |
EP1326996A4 (en) * | 2000-09-14 | 2005-08-24 | Univ California | Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma |
DE10051427C1 (en) * | 2000-10-17 | 2002-06-13 | Adam Mueller | Process for the production of an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material and cannabis extracts |
US7025992B2 (en) * | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
CH695661A5 (en) * | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmaceutical composition. |
US20080057117A1 (en) * | 2002-02-15 | 2008-03-06 | Forschungs Institut Miscia Verenfur Krebsforschung | Pharmaceutical composition made up of cannibus extracts |
IL148244A0 (en) * | 2002-02-19 | 2002-09-12 | Yissum Res Dev Co | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
US7285687B2 (en) * | 2002-04-25 | 2007-10-23 | Virginia Commonwealth University | Cannabinoids |
US6946150B2 (en) * | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
GB2418612A (en) * | 2004-10-01 | 2006-04-05 | Gw Pharma Ltd | Inhibition of tumour cell migration with cannabinoids |
AU2006231452B2 (en) * | 2005-04-01 | 2011-05-26 | Intezyne Technologies, Inc. | Polymeric micelles for drug delivery |
US7968594B2 (en) * | 2005-04-27 | 2011-06-28 | Gw Pharma Limited | Pharmaceutical compositions for the treatment of pain |
JP2008540570A (en) * | 2005-05-13 | 2008-11-20 | ユニメッド・ファーマシューティカルズ・インコーポレーテッド | Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting |
KR100675281B1 (en) * | 2005-09-05 | 2007-01-29 | 삼성전자주식회사 | Semiconductor device having decoupling capacitor and method of fabricating the same |
WO2008144475A1 (en) * | 2007-05-17 | 2008-11-27 | California Pacific Medical Center | Methods and compositions for treating cancer |
GB2471987B (en) * | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
UA71391U (en) * | 2012-01-05 | 2012-07-10 | Харьковский Государственный Университет Питания И Торговли | Method for producing processed cheese spread |
-
2008
- 2008-06-04 GB GB1101072A patent/GB2475183B/en active Active
- 2008-06-04 GB GB0810203.0A patent/GB2460672B/en active Active
-
2009
- 2009-06-03 TW TW098118352A patent/TWI469777B/en active
- 2009-06-03 AR ARP090101999A patent/AR072002A1/en unknown
- 2009-06-04 SG SG2013043088A patent/SG191643A1/en unknown
- 2009-06-04 WO PCT/GB2009/050620 patent/WO2009147438A1/en active Application Filing
- 2009-06-04 JP JP2011512221A patent/JP5674649B2/en active Active
- 2009-06-04 PT PT97578108T patent/PT2320881T/en unknown
- 2009-06-04 AU AU2009254935A patent/AU2009254935B2/en active Active
- 2009-06-04 DK DK09757810.8T patent/DK2320881T3/en active
- 2009-06-04 UA UAA201015910A patent/UA104589C2/en unknown
- 2009-06-04 MY MYPI2010005535A patent/MY156264A/en unknown
- 2009-06-04 KR KR1020117000056A patent/KR20110053944A/en not_active Application Discontinuation
- 2009-06-04 EP EP09757810.8A patent/EP2320881B1/en active Active
- 2009-06-04 NZ NZ589373A patent/NZ589373A/en unknown
- 2009-06-04 CA CA2726257A patent/CA2726257C/en active Active
- 2009-06-04 CN CN200980120573.5A patent/CN102083426B/en active Active
- 2009-06-04 EP EP16201983.0A patent/EP3213748B1/en active Active
- 2009-06-04 RU RU2010154672/14A patent/RU2543034C2/en active
- 2009-06-04 ES ES16201983T patent/ES2887084T3/en active Active
- 2009-06-04 ES ES09757810.8T patent/ES2653200T3/en active Active
- 2009-06-04 US US12/996,167 patent/US20110086113A1/en not_active Abandoned
- 2009-06-04 BR BRPI0911384A patent/BRPI0911384A8/en not_active Application Discontinuation
- 2009-06-04 MX MX2010013036A patent/MX2010013036A/en not_active Application Discontinuation
-
2010
- 2010-11-29 ZA ZA2010/08558A patent/ZA201008558B/en unknown
- 2010-12-02 IL IL209739A patent/IL209739A0/en active IP Right Grant
- 2010-12-15 CO CO10157628A patent/CO6341551A2/en not_active Application Discontinuation
-
2014
- 2014-10-31 JP JP2014222892A patent/JP2015057411A/en active Pending
-
2018
- 2018-05-01 US US15/968,633 patent/US20190099492A1/en not_active Abandoned
-
2020
- 2020-11-23 US US17/102,109 patent/US20210069333A1/en active Pending
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210069333A1 (en) | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents | |
US20200138771A1 (en) | Anti-tumoural effects of cannabinoid combinations | |
GB2478074A (en) | THC and CBD for use in the treatment of tumours | |
GB2478072A (en) | THC and CBD for use in the treatment of brain tumours |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2320881 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180228 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/352 20060101ALI20200922BHEP Ipc: A61K 45/06 20060101ALI20200922BHEP Ipc: A61K 31/282 20060101ALI20200922BHEP Ipc: A61P 43/00 20060101ALI20200922BHEP Ipc: A61K 31/53 20060101ALI20200922BHEP Ipc: A61K 31/17 20060101ALI20200922BHEP Ipc: A61P 25/04 20060101ALI20200922BHEP Ipc: A61K 31/138 20060101AFI20200922BHEP Ipc: A61K 31/185 20060101ALI20200922BHEP Ipc: A61K 31/4535 20060101ALI20200922BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20210428 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2320881 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009063972 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1420986 Country of ref document: AT Kind code of ref document: T Effective date: 20210915 Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2887084 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211221 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1420986 Country of ref document: AT Kind code of ref document: T Effective date: 20210818 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211118 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211118 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211220 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009063972 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20220519 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20220630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220604 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220604 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230530 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230620 Year of fee payment: 15 Ref country code: FR Payment date: 20230620 Year of fee payment: 15 Ref country code: DE Payment date: 20230620 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230630 Year of fee payment: 15 Ref country code: GB Payment date: 20230608 Year of fee payment: 15 Ref country code: ES Payment date: 20230719 Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20090604 |